Further Studies

• Long term safety and efficacy up to 5 years

• Durability of seroconversion up to 5 years

• ADV dosing guidelines in chronic hepatitis B patients with renal impairment

• Safety and efficacy in pediatrics, pregnancy, and other populations

• Drug-drug interaction studies

• Co-infection (Studies ACTG 5127, 5149)

• Combination therapy in treatment-naïve patients

• Resistance surveillance

Previous slide

Next slide

Back to first slide

View graphic version